355
Participants
Start Date
March 18, 2024
Primary Completion Date
April 10, 2025
Study Completion Date
May 1, 2025
NNC0519-0130
NNC0519-0130 will be administered subcutaneously.
Placebo
Placebo will be administered subcutaneously.
Tirzepatide
Tirzepatide will be administered subcutaneously.
Momentum Clinical Research Darlinghurst, Darlinghurst
Northern Beaches Clinical Research, Brookvale
Paratus Clinical, Blacktown
Novatrials, Kotara
Austin Health, Metabolic Disorders Centre, Heidelberg Heights
Emeritus Research Melbourne, Camberwell
Paratus Clinical, Herston
University of Sunshine Coast, Sippy Downs
CMAX Clinical Research, Norwood
Preferred Primary Care Physicians_Pittsburgh, Pittsburgh
Centennial Medical Group, Columbia
Washington Cntr Weight Mgmt, Arlington
National Clin Res Inc., Richmond
Health Res of Hampton Roads, Newport News
TPMG Clinical Research, Newport News
Medication Mgmnt, LLC_Grnsboro, Greensboro
PharmQuest Life Sciences LLC, Greensboro
Physicians East Endocrinology, Greenville
Accellacare, Wilmington
Piedmont Healthcare, Statesville
Spartanburg Medical Research, Spartanburg
Medical University Of South Carolina, Charleston
Northeast Research Institute, Fleming Island
Jacksonville Ctr For Clin Res, Jacksonville
Nature Coast Clinical Research, Crystal River
L-MARC Research Center, Louisville
Remington Davis Inc, Columbus
Midwest Inst For Clin Res, Indianapolis
Velocity Clin. Res Valparaiso, Valparaiso
Cedar-Crosse Research Center, Chicago
StudyMetrix Research LLC, City of Saint Peters
Unity Health-Searcy Medical Center, Searcy
Lynn Institute of Norman, Norman
Velocity Clinical Res-Dallas, Dallas
North Texas Endocrine Center, Dallas
UT Southwestern Medical Center - Lingvay, Dallas
DCOL Ctr for Clin Res, Longview
FDRC, Costa Mesa
Diablo Clinical Research, Inc., Walnut Creek
Family Practice Center of Wadsworth Inc., Wadsworth
The University of Penn Center, Philadelphia
Velocity Clin Res Providence, East Greenwich
Holston Medical Group Pc, Bristol
OCROM Clinic, Suita-shi
ToCROM Clinic, Tokyo
Lead Sponsor
Novo Nordisk A/S
INDUSTRY